Genome Research Limited

Genome Research Limited

The Institute and the wider Wellcome Genome Campus operate under the name of Genome Research Limited (GRL). GRL was established in 1992 and is a wholly owned subsidiary of the Wellcome Trust. In 2012, the Wellcome Trust Board of Governors agreed to place all activities on the Wellcome Genome Campus, including the Sanger Institute, under the auspices of GRL in order to facilitate the development of a long term and coherent strategy for the Campus and all activities on it.

Through the activities of the Wellcome Sanger Institute and the wider Genome Campus, the ambition of GRL over the next 20 years is to strengthen its well-established scientific foundations and to build on them, such that the Wellcome Genome Campus becomes an international centre for scientific, business, cultural and educational activities emanating from Genomes and BioData. To achieve this vision GRL’s Mission is to:

  • Advance understanding of biology using genome sequences and biodata.
  • Apply genome science for human health and other societal benefits.
  • Foster discussion of the scientific, medical and wider implications of genomes.

Genome Research Limited Board of Directors

Jeremy Farrar (Chair)

Jeremy Farrar is the Director of Wellcome. Before joining Wellcome in October 2013, Jeremy Farrar was Director of the Oxford University Clinical Research Unit in Vietnam for 18 years. His research interests were infectious diseases, tropical health and emerging infections.

Daniel Abrams

Daniel Abrams will also Chair the GRL Audit and Risk Committee. Daniel is non-executive director of BioCity Nottingham, a biotech incubator; and non-executive director of Cambridge University Hospitals NHS Foundation Trust.

Professor Dame Kay Davies

Kay Davies is the Dr Lee’s Professor of Anatomy in the Department of Physiology, Anatomy and Genetics and Director of the MRC Functional Genomics Unit at the University of Oxford. Her research interests lie in the molecular analysis and development of treatment for human genetic disease, particularly, Duchenne muscular dystrophy (DMD) and the application of genomics for the analysis of neurological disorders. She is a founding fellow of the UK Academy of Medical Sciences and was elected a Fellow of the Royal Society in 2003. She also sits on the board of Genomics England.

Professor Rolf Heuer

Rolf Heuer is ex Director General of CERN.

Dr Nicole Mather

Nicole Mather leads Life Sciences for IBM based in GBS in London. Nicole's career has been focused in Healthcare and Life Sciences, with over fourteen years experience as a strategy consultant at AT Kearney and Deloitte. More recently, Nicole led the Office for Life Sciences in UK Government. Nicole has a DPhil in Genomics from the University of Oxford and is a Non-Executive Director of the Health Research Authority.

Paul Schreier

Paul Schreier is Wellcome’s Chief Operating Officer. Previously he was Chief Executive Officer of Hakluyt & Company, Deputy Vice-Chancellor and COO of Macquarie University in Australia and a senior civil servant advising the Australian Prime Minister and Cabinet.

Professor Sir Jim Smith

Jim Smith is Director of Science for Wellcome, developing its science research strategy and managing a broad research portfolio. His previous roles include Director of the Wellcome Trust/Cancer Research UK Gurdon Institute and Director of the MRC National Institute for Medical Research (NIMR), where he oversaw its transition to the Francis Crick Institute. More recently, he has been Deputy CEO and Chief of Strategy at the Medical Research Council, and Director of Research and Group Leader at the Francis Crick Institute.

Cilla Snowball

Cilla Snowball is a Governor of Wellcome and a non-executive director at Derwent London plc. Previously she was Group CEO and Group Chairman of creative agency AMV BBDO, chair of the Women’s Business Council, and a trustee of Comic Relief.